BioMarin gets its dwarfism drug in the FDA's door — but can they change regulators’ minds about a longer follow up?
BioMarin’s dwarfism drug has secured a place in the FDA’s review line, but disagreements with regulators on just how long the follow-up period should be …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
